JOEL MORGAN: Open Payments
NPI 1558360784 · VALDOSTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$86,137 in 149 payments from 16 companies in 2025. Trend: 2023 $102,481 · 2024 $90,858 · 2025 $86,137
Speaker / faculty: $50,878Consulting: $22,420Honoraria: $4,975Travel & lodging: $4,939Food & beverage: $2,925
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 41 | $32,563 |
| E.R. Squibb & Sons, L.L.C. | 23 | $17,367 |
| Teva Pharmaceuticals USA, Inc. | 11 | $11,842 |
| Alkermes, Inc. | 26 | $11,533 |
| ABBVIE INC. | 15 | $7,205 |
| Supernus Pharmaceuticals, Inc. | 9 | $5,059 |
| Axsome Therapeutics, Inc. | 6 | $162 |
| Almatica Pharma LLC | 4 | $89 |
| Otsuka America Pharmaceutical, Inc. | 2 | $85 |
| Lundbeck LLC | 3 | $68 |
Products named: CAPLYTA, AUSTEDO XR, LYBALVI, COBENFY, VRAYLAR, Qelbree, Auvelity, REXULTI.
Industry payments across GA — which companies pay providers there.
